Gyre Therapeutics Q1 revenue rises 2% but misses analyst estimates

Gyre Therapeutics

07/05/2026 11:16

Overview

US biopharmaceutical firm's Q1 revenue rose 2% yr/yr, missing analyst expectations

Company posted a net loss as operating expenses rose, including Cullgen acquisition costs

Completed $300 mln all-stock acquisition of Cullgen, expanding pipeline into new disease areas

Outlook

Gyre Therapeutics affirms 2026 revenue guidance of $100.5 mln to $111.0 mln

Company is evaluating pipeline and clinical strategy after Cullgen acquisition; updates expected after review

Result Drivers

NEW PRODUCT SALES - Revenue growth was primarily driven by increased sales of Contiva and Etorel, which contributed $0.5 mln and $0.7 mln, respectively, offsetting a decline in ETUARY sales

RISING OPERATING EXPENSES - Higher selling, marketing, and research costs, including early-stage launch activities and clinical trials, drove a significant increase in operating expenses

CULLGEN ACQUISITION COSTS - Transaction costs related to the Cullgen acquisition contributed to the rise in expenses and operating loss

Company press release: ID:nGNX4sH2k6

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$22.52 mln
$31.61 mln (3 Analysts)
Q1 Net Income
-$9.86 mln
Q1 Operating Profit
-$9.36 mln
Q1 Pretax Profit
-$9.24 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

Wall Street's median 12-month price target for Gyre Therapeutics Inc is $18.00, about 123.9% above its May 6 closing price of $8.04

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)